Observational studyThe pharmacogenomics journal2026
CYPRI: a clinical decision-making tool to select psychiatric patients for pharmacogenetic testing.
Observational study in The pharmacogenomics journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pharmacogenetic (PGx) testing of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 is increasingly utilised to personalise psychopharmacological treatment, but clear criteria for patient selection are lacking. We developed and conducted a pilot evaluation of a clinical decision-making tool, the CYPRI (CYP Pharmacogenetic Risk Index), which uses routinely available clinical and pharmacological data to estimate the likelihood of a clinically relevant and actionable PGx testing result. A pilot observational study involving 34 patients was conducted at Psychiatric Hospital Bohnice in Prague, Czech Republic. A significant correlation was observed between the CYPRI score and the IMPACT score (ordinal logistic regression: t = 3.279, p = 0.0011; Kendall's τ = 0.46, p = 0.0011). Discriminative ability was high, with an area under the curve (AUC) of 0.83 (95% CI: 0.69-0.97), based on ROC analysis performed using two outcome categories (0-2 vs. ≥ 2 points of IMPACT score). The optimal cut-off was 4. The CYPRI score offers a straightforward method to prioritise patients for PGx testing, potentially enhancing cost-effectiveness and clinical outcomes in psychiatric care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.